Abstract

BackgroundTo compare the efficacy and safety of right internal jugular vein (IJV) approach and right innominate vein (INV) approach for US-guided totally implantable venous access devices (TIVADs), and to explore the advantages and disadvantages of the two approaches.MethodsSix hundred and nineteen adult patients had long-term infusion and chemotherapy needs and inconvenience of peripheral venous infusion. Right INV approach was used to implant 339 cases of TIVADs, and right IJV approach was used to implant 280 cases of TIVADs. The success rate of one-time catheterization and the incidence of complications in the two groups were retrospectively analyzed.ResultsAll patients were successfully implanted in TIVAD. The success rates of one-time puncture in INV group and IJV approach group were 98.53% (334/339) and 95.36% (267/280), respectively. There was significant difference between the two groups (P = 0.020). The incidence of perioperative complications and long-term complications in the right INV group were 1.18% (4/339) and 3.54% (12/339), respectively, while those in the right IJV group were 1.43% (4280) and 3.93% (11280). There was no significant difference in the incidence of perioperative or long-term complications between the two groups (P = 0.785, P = 0.799, respectively).ConclusionsUS-guided TIVADs via the right INV approach and the right IJV approach are both safe and reliable. The right INV approach improves the one-time puncture success rate, as long as the technique is properly operated, serious complications rarely occur.

Highlights

  • To compare the efficacy and safety of right internal jugular vein (IJV) approach and right innominate vein (INV) approach for US-guided totally implantable venous access devices (TIVADs), and to explore the advantages and disadvantages of the two approaches

  • The application of a totally implantable venous access device (TIVAD) is regarded as a leap-forward development of infusion technology, and it significantly reduces the risk of drug infusions, especially chemotherapeutic drug infusions [1]

  • TIVAD has been widely used in clinical application, which is superior to other long-term intravenous infusion pathways and is the best choice for cancer patients [2]

Read more

Summary

Introduction

To compare the efficacy and safety of right internal jugular vein (IJV) approach and right innominate vein (INV) approach for US-guided totally implantable venous access devices (TIVADs), and to explore the advantages and disadvantages of the two approaches. The application of a totally implantable venous access device (TIVAD) is regarded as a leap-forward development of infusion technology, and it significantly reduces the risk of drug infusions, especially chemotherapeutic drug infusions [1]. Internal jugular vein (IJV) approach has become the most commonly used approach in clinical application because of its high success rate and low complications [4, 5]. The reports of US-guided INV approach for TIVADs implantation in adult patients are limited [9]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call